Chen, Y., Kingham, K., Ford, J. M., Rosing, J., Van Dam, J., Jeffrey, R. B., Longacre, T. A., Chun, N., Kurian, A., Norton, J. However, epidemiologic studies on circulating melatonin are limited because melatonin is secreted at night, yet most epidemiologic studies collect blood during the day when melatonin levels are very low, and assays are lacking that are ultrasensitive to detect low levels of melatonin reliably.To assess the performance of a refined radioimmunoassay in measuring morning melatonin among women.We used morning serum samples from 47 postmenopausal women ages 48-80 years without a history of breast cancer who participated in the San Francisco Bay Area Breast Cancer Study, including 19 women who had duplicate measurements. Gupta, T., Purington, N., Liu, M., Han, S., Sledge, G., Schapira, L., Kurian, A. W. The effect of COVID-19 on telehealth: next steps in a post-pandemic life. Wapnir, I. L., Kingham, K. E., Mills, M., Ford, J. M., Kurian, A. W. Screening for founder and recurrent BRCA mutations in Hong Kong and US Chinese populations. All but three, were identified in general population studies. View details for DOI 10.1056/NEJMoa2005936, View details for DOI 10.1200/CCI.21.00145. Participants completed questionnaires to measure quality of life (FACT-G), functional social support (Duke-UNC FSSQ), distress (PHQ-4), decision regret (DRS), and SM use.In total, 75.8% of the sample reported using SM. However, these drugs are associated with side effects. Since their inception in 2000, the Cancer Intervention and Surveillance Network (CISNET) breast cancer models have collaborated to use a nationally representative core of common input parameters to represent key components of breast cancer control in each model. How Much is Todd Chrisleys Net Worth in 2023? We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. Use of the 21-gene recurrence score (RS) did not change among node-negative/micrometastasis patients, and increasing RS use in node-positive patients accounted for one-third of the chemotherapy decline. To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in Studies report a 4-16% prevalence of mutations other than BRCA1/2 among patients who meet evidence-based practice guidelines for BRCA1/2 testing, with a high rate (15-88%) of uninterpretable variants of uncertain significance. Overall, 1301 (43.9%) patients considered CPM (601 [24.8%] considered it very strongly or strongly); only 395 (38.1%) of them knew that CPM does not improve survival for all women with breast cancer. Clinicians should collect toxicity data routinely and offer early intervention. For more information, please contact Charlene Kranz, (650) 498 - 7977. View details for DOI 10.1016/j.jval.2020.01.018. Google Cloud CEO Thomas Kurian Gives Partner Program An 'A' Donna Goodison October 12, 2021, 09:26 AM EDT In an exclusive interview with CRN, Kurian makes his case for the Google Cloud Partner. Rafat, M., Aguilera, T. A., Vilalta, M., Bronsart, L. L., Soto, L. A., von Eyben, R., Golla, M. A., Ahrari, Y., Melemenidis, S., Afghahi, A., Jenkins, M. J., Kurian, A. W., Horst, K. C., Giaccia, A. J., Graves, E. E. Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy. Of the 63% associated with treatment, 31% (model range, 22%-37%) was associated with chemotherapy, 27% (model range, 18%-36%) with hormone therapy, and 4% (model range, 1%-6%) with trastuzumab. Existing research examining barriers to addressing patients' sexual health concerns has focused on discrete characteristics of the provider-patient interaction without considering the broader context in which these interactions occur. Early user testing demonstrated ease of use and app feasibility.TOGETHERCare, a novel mobile app, was developed with user input to track the care partner's health and report on survivor symptoms during home care. Evidence-based guidelines recommend cascade genetic counseling and testing for hereditary cancer syndromes, providing relatives the opportunity for early detection and prevention of cancer. Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians. Most population-based cancer databases lack information on metastatic recurrence. Kurian, A. W., Abrahamse, P., Hamilton, A. S., Caswell-Jin, J. L., Gomez, S. L., Hofer, T. J., Ward, K. C., Katz, S. J. This significant reduction in BM risk among PLCs detected through LDCT-screening persisted in subgroups of early-stage PLC participants (HR 0.47, p=0.002) and those who underwent surgery (HR 0.37, p=0.001).Early detection of PLC using LDCT-screening is associated with lower risk of BM after PLC diagnosis based on a large population-based study. A total of 637 women developing incident TNBC and 511 women developing incident HGSOC were matched with cancer-free controls (1841 and 2982, respectively) in a nested case-control design. It is Clinician discussions about recurrence risk should address uncertainty and relevance of family and personal history. Lifetime risk of triple-negative breast cancer is highest in black women (1.98%, 1.80-2.17%), compared to 0.77% (0.67-0.88%) for Asians, 1.04% (0.96-1.13%) for Hispanics and 1.25% (1.20-1.30%) for whites. Model input parameters were derived from meta-analyses, clinical trials, and large observational data. Difficulty of access to cascade testing, particularly for family members that do not live in the United States, was also of concern. We used Cox regression to estimate risk associations with log-transformed weight and BMI after adjusting for underlying familial risk. Helping patients to maximize their autonomy in breast cancer decision-making is an important aspect of patient-centered care. Overall survival and time to next treatment were evaluated. To guide decisions informed by multiple health outcomes, we provide an online tool for joint use by patients with their physicians (http://brcatool.stanford.edu). Observed subtype distributions may explain the poorer breast cancer survival previously observed among AYAs. View details for DOI 10.1158/1055-9965.EPI-08-1090, View details for DOI 10.1200/JCO.2008.20.7191, View details for Web of Science ID 000262894400031. HLA alleles (n=175) with info scores greater than 0.8 and frequencies greater than 0.01 were included (resolution at two-digit level: 71; four-digit level: 104). RPA was not associated with risk of second BC events.Findings support that RPA is associated with lower all-cause mortality in women with BC, particularly in women with BRCA1/2 PVs. The combination of PM and PO at age 40 improves survival more than any single intervention, yielding 24% survival gain for BRCA1 and 11% for BRCA2 mutation carriers. In this review, we summarize the current understanding of pathogenic germline gene mutations associated with TNBC and the early detection and prevention strategies for women at risk of developing this high-risk breast cancer subtype. In this approach, we impute missing values using regression models for each variable, conditional on the other variables in the data. If a patient with higher pretest risk saw a surgeon at the 5th percentile of the surgeon distribution, she would have a 26.3% (95% CI, 21.9%-31.2%) probability of testing compared with 72.3% (95% CI, 66.7%-77.2%) if she saw a surgeon at the 95th percentile.In this study, the attending surgeon was associated with the receipt of genetic testing after a breast cancer diagnosis. However, CTC transcriptional profiling is limited by leukocyte contamination; an approach to surmount this problem is single cell analysis. is a Professor of Medicine and of Epidemiology and Population Health at Stanford University School of Medicine. View details for DOI 10.1002/cncr.31731 The use of common inputs also enhances inferences about the results, and provides a range of reasonable results based on variations in model structure, assumptions, and methods of use of the input values. In a direct comparison, the 86-SNP PRS outperformed a previously described PRS of 77 SNPs.The validation and implementation of a PRS for women without pathogenic variants in known breast cancer susceptibility genes offers potential for risk stratification to guide surveillance recommendations. BRCA1 mutations were more common among whites (67 vs. 42%, p=0.02), and BRCA2 mutations among Asians (58 vs. 37%, p=0.04). Thomas Kurian married a woman from Boston in typical style. Forty-three percent of the patients were treated at the academic center only, 42 percent at the community center only, and 16 percent of the patients obtained care at both health care organizations. Perceptions of "moderate, high or very high" risk were considered descriptive overestimates. Patients with early-onset breast and/or ovarian cancer frequently wish to know if they inherited a mutation in one of the cancer susceptibility genes, BRCA1 or BRCA2. Is He Divorced? View details for DOI 10.1007/s10689-012-9577-8. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Whereas, his mother lived in Sri Lanka but born to Indian parents. Gomez, S. L., Press, D. J., Lichtensztajn, D., Keegan, T. H., Shema, S. J., Le, G. M., Kurian, A. W. Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort. Genetic instruments were single nucleotide polymorphisms (SNPs) associated in UK Biobank with wrist-worn accelerometer-measured overall physical activity (nsnps=5) or sedentary time (nsnps=6), or accelerometer-measured (nsnps=1) or self-reported (nsnps=5) vigorous physical activity.Greater genetically-predicted overall activity was associated with lower breast cancer overall risk (OR=0.59; 95% confidence interval (CI) 0.42 to 0.83 per-standard deviation (SD;~8 milligravities acceleration)) and for most case-groups. Blayney, D. W., Seto, T., Hoang, N., Lindquist, C., Kurian, A. W. Impact of COVID-19 on breast cancer care at a Bay Area academic center. Our findings demonstrate that profiling CTCs on a cell-by-cell basis is possible and may facilitate the application of 'liquid biopsies' to better model drug discovery. COMMUNICATING COMPLEXITY: ANALYSIS OF THE COMMUNICATION OF CANCER GENETIC TEST RESULTS THREE MONTHS POST DISCLOSURE. Most publications on ductal lavage for cell collection report cannulating fluid-yielding ducts only. View details for Web of Science ID 000207843700006. Hall, E., Parikh, D., Gupta, T., Caswell, J., Mills, M., Kingham, K., Koff, R., Ford, J. M., Kurian, A. W. Recent time trends in chemotherapy use and oncologists' chemotherapy recommendations for early-stage, hormone receptor-positive breast cancer. The proportion of mastectomies that were nipple-sparing increased over time (1988, 0.2%; 2013, 5.1%) and with neighborhood socioeconomic status, and decreased with age and stage. - Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for To summarize evidence on the prevalence and spectrum of BRCA1 and BRCA2 BRCA1/2 mutations across racial and ethnic groups and discuss implications for clinical practice.The prevalence of BRCA1/2 mutations is comparable among breast cancer patients of African, Asian, white, and Hispanic descent: approximately 1-4% per gene. We identified 31 potential novel loci with the lead variant showing an association with breast cancer risk at P, View details for DOI 10.1038/s41467-020-15046-w, View details for PubMedCentralID PMC7057957. Agrawal, A., Benedict, C., Nouriani, B., Medina, J., Kurian, A. W., Spiegel, D. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. We built a gene expression-based classifier of imaging subtypes and tested their prognostic significance in five additional cohorts with publically available gene expression data but without imaging data (n=1160).Three distinct imaging subtypes, i.e., homogeneous intratumoral enhancing, minimal parenchymal enhancing, and prominent parenchymal enhancing, were identified and validated. performed in the laboratory, iniparib is a novel investigational anti-cancer agent that Resulting regression model approximations include indicators for missingness, interactions, or other functions of the missingness not at random missingness model and observed data. Kurian, A. W., Abrahamse, P., Ward, K. C., Hamilton, A. S., Deapen, D., Berek, J. S., Hoang, L., Yussuf, A., Dolinsky, J., Brown, K., Slavin, T., Hofer, T. P., Katz, S. J. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer. Cause-specific proportional hazards models estimated SPLC risk. Emerging Opportunity of Cascade Genetic Testing for Population-Wide Cancer Prevention and Control. Kurian's next goal for Google Cloud is to hit $34 billion in annual revenue by 2023, a source says. The MA-PRS is a combination of three ancestry-specific PRSs on the basis of genetic ancestral composition. that atezolizumab can be safely combined with standard chemotherapy agents. Breast oncology precision medicine: Genomic testing and treatment at the population level. Smoking cessation after IPLC diagnosis may reduce the risk of SPLC. Surveys were sent 2months post-surgery, (70% response rate, n=5080). The rate of a variant of uncertain significance (VUS) result was higher in nonwhites than whites (36% vs. 27%; P=2E-4). ATM PVs are associated with multiple cancer risks and, while professional society guidelines support that carriers are eligible for increased breast and pancreatic cancer screening, increased screening for prostate and gastric cancer may also be warranted. Women receive broad cancer risk figures that are not personalised (e.g., 44-63% lifetime risk of breast cancer for those with PALB2). Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and Sexual orientation and gender identity data are not collected by most hospitals or cancer registries; thus, little is known about the quality of breast cancer treatment for patients from sex and gender minority (SGM) groups.To evaluate the quality of breast cancer treatment and recurrence outcomes for patients from SGM groups compared with cisgender heterosexual patients.Exposure-matched retrospective case-control study of 92 patients from SGM groups treated at an academic medical center from January 1, 2008, to January 1, 2022, matched to cisgender heterosexual patients with breast cancer by year of diagnosis, age, tumor stage, estrogen receptor status, and ERBB2 (HER2) status.Patient demographic and clinical characteristics, as well as treatment quality, as measured by missed guideline-based breast cancer screening, appropriate referral for genetic counseling and testing, mastectomy vs lumpectomy, receipt of chest reconstruction, adjuvant radiation therapy after lumpectomy, neoadjuvant chemotherapy for stage III disease, antiestrogen therapy for at least 5 years for estrogen receptor-positive disease, ERBB2-directed therapy for ERBB2-positive disease, patient refusal of an oncologist-recommended treatment, time from symptom onset to tissue diagnosis, time from diagnosis to first treatment, and time from breast cancer diagnosis to first recurrence. Across all panels, the rate of pathogenic variants (15%) did not differ significantly between racial groups. To evaluate patient experiences with decisions regarding radiation therapy (RT) for ductal carcinoma in situ (DCIS), and to assess clinician views on the role of RT for DCIS with favorable features in the present era.A sample of women with newly diagnosed breast cancer from the population-based Georgia and Los Angeles County Surveillance, Epidemiology, and End Results (SEER) registries were sent surveys approximately 2months after undergoing breast-conserving surgery (BCS), with a 70% response rate. Conclusion Heterogeneous enhancement patterns of tumor-adjacent parenchyma at MR imaging are associated with the tumor necrosis signaling pathway and poor survival in breast cancer. The twin brothers arrived at the U.S. at age 17 eventually attending Princeton University. The Phase Kwong, A., Chau, W., Law, F. F., Kurian, A., Ford, J. M., West, D. W., Ma, E. K. Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. is to compare efficacy and safety of a treatment with exemestane + everolimus to exemestane + Furthermore, we demonstrate that experimental manipulation of DDR pathways highlighted by human genetics increases fertility and extends reproductive life in mice. Afghahi, A., Rigdon, J., Purington, N., Desal, M., Pierson, E., Mathur, M., Thompson, C. A., Curtis, C., West, R. B., Horst, K. C., Gomez, S., Ford, J. M., Sledge, G. W., Kurian, A. W. Safety of multiplex gene testing for inherited cancer risk: Interim analysis of a clinical trial. A., Sickles, E. A., Brenner, J., Lindfors, K. K., Joe, B. N., Leung, J. T., Feig, S. A., Ojeda-Fournier, H., Kurian, L. W., Love, E., Ryan, L., Ikeda, D. M. Chromosomal copy number alterations (CNAs) for risk assessment of ductal carcinoma in situ (DCIS). Overestimators (OR.50, CI 0.31-0.81) or those who perceived zero risk (OR.46, CI 0.29-0.72) more often said that their doctor did not discuss risk. Breast cancer incidence is higher among black women than white women before age 40 years, but higher among white women than black women after age 40 years (black-white crossover). Doctor-patient communication is the primary way for women diagnosed with breast cancer to learn about their risk of distant recurrence. Few factors other than family history were significantly associated with either type of overestimation. All three mindsets were independent correlates of HRQOL, explaining 6-15% unique variance in HRQOL, even after accounting for demographic and medical factors.Mindsets about illness are significantly associated with HRQOL in cancer survivors. Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR=1.035, 95% CI=0.859-1.246, P=0.718 and OR=0.798, 95% CI=0.482-1.322, P=0.381 respectively), nor in specific high-risk subgroups or breast cancer subtypes. Kwong, A., Shin, V. Y., Ho, J. C., Kang, E., Nakamura, S., Teo, S., Lee, A. S., Sng, J., Ginsburg, O. M., Kurian, A. W., Weitzel, J. N., Siu, M., Law, F. B., Chan, T., Narod, S. A., Ford, J. M., Ma, E. S., Kim, S. Clinical validity and actionability of multigene tests for hereditary cancers in a large multi-center study, Lincoln, S., Kurian, A. W., Desmond, A., et al. Nipple fluid production and atypical breast duct cells in women at high risk of breast cancer have been associated with further increased risk. The two models showed similar discrimination in each racial/ethnic group, discriminating least well in Hispanics. Exploratory simulation of the protective SNP suggested improved IBIS/Tyrer-Cuzick calibration for Hispanic women (O/E ratio = 0.80; 95% CI, 0.66-0.96).The IBIS/Tyrer-Cuzick model is well calibrated for several racial/ethnic groups over 2 decades of follow-up. Petkov, V., Kurian, A. W., Jakubowski, D. M., Shak, S. Abstract P6-08-07: Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations. clinical exam or radiology will be randomized to either neoadjuvant treatment with In European women from BCAC, higher PRS313 was associated with better OS and BCSS: hazard ratio (HR) 0.96 (95% CI, 0.94 to 0.97) and 0.96 (95% CI, 0.94 to 0.98), but the association disappeared after adjustment for clinicopathologic characteristics (and treatment): OS HR, 1.01 (95% CI, 0.98 to 1.05) and BCSS HR, 1.02 (95% CI, 0.98 to 1.07). View details for DOI 10.1093/jncics/pky062. Data analyses were conducted using chi-square and t tests. We identified 6,004 women diagnosed with Stage I-III breast cancer at KPNC during 2004-2007; 2,669 (44.5 %) received at least one chemotherapy infusion at KPNC within 12 months of diagnosis. For your information, Thomas Kurian is a married man. After controlling for patient and tumor characteristics, second opinion use was not associated with chemotherapy receipt (OR, 1.04; 95% CI, 0.71-1.52).Second opinion use was low (<10%) among patients with early-stage breast cancer, and high decision satisfaction regardless of second opinion use suggests little unmet demand. Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes. Patients and health care providers rated the decision tool highly on measures of usability and clinical relevance. Cancer incidence has been more extensively studied than cancer survival, though results are inconsistent as some large meta-analyses have not found an association, while other studies have reported improved cancer outcomes with the use of statins. Afghahi, A., Forgo, E., Mitani, A. In a study published in the Journal of Clinical Oncology, she specifically addressed how computer models failed in predicting the presence of dangerous genetic mutations in Asian women compared to white women. Approximately half of patients (57% at higher pretest risk, 42% at average risk) discussed results with a genetic counselor. Second Opinions From Medical Oncologists for Early-Stage Breast Cancer Prevalence, Correlates, and Consequences. Ricker, C. N., Koff, R. B., Qu, C. n., Culver, J. n., Sturgeon, D. n., Kingham, K. E., Lowstuter, K. n., Chun, N. M., Rowe-Teeter, C. n., Lebensohn, A. n., Levonian, P. n., Partynski, K. n., Lara-Otero, K. n., Hong, C. n., Petrovchich, I. M., Mills, M. A., Hartman, A. R., Allen, B. n., Ladabaum, U. n., McDonnell, K. n., Ford, J. M., Gruber, S. B., Kurian, A. W., Idos, G. E. Measuring serum melatonin in postmenopausal women: Implications for epidemiologic studies and breast cancer studies. Notably, failing to impute cases with missing receptor status leads to overestimation of survival because those with missing receptor status tend to have worse prognostic features. Caswell-Jin, J., Shafaee, M., Liu, M., Xiao, L., John, E. M., Bondy, M., Kurian, A. W. Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. and help prevent the tumor from returning. The influence of environmental factors on cancer development in These findings emphasize the need to address challenges in personalized communication about genetic testing. Stanford is currently not accepting patients for this trial. Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. We assessed whether lifelong physical activity or sedentary time, assessed using genotype, may be causally associated with breast cancer risk overall, pre/post-menopause, and by case-groups defined by tumour characteristics.We performed two-sample inverse-variance-weighted MR using individual-level Breast Cancer Association Consortium case-control data from 130 957 European-ancestry women (69 838 invasive cases), and published UK Biobank data (n=91 105-377 234). View details for DOI 10.1093/jnci/djab097. View details for DOI 10.1001/jamaoncol.2015.2690, View details for Web of Science ID 000383675900013, View details for Web of Science ID 000363715903015. Candidate polygenic risk scores (PRSs) as predictors of personal breast cancer history were developed through multivariable logistic regression models adjusted for age, cancer history, and ancestry. View details for DOI 10.1038/s41467-020-17680-w. We present the current pathogenic mutation spectrum of BRCA1/BRCA2 genes in patients with breast cancer in various Asian populations. The indications for testing and utility of these 2 tests differ, and guidelines recommend that germline analysis follow tumor sequencing in certain patients to determine whether particular variants are of somatic or germline origin. Broad clinical experience with such follow-up testing has not yet been thoroughly described.To examine the yield and utility of germline testing following tumor DNA sequencing in a large, diverse patient population.A retrospective cohort study examined germline testing through a laboratory supporting multiple academic and community clinics. Mendelian randomisation (MR) assesses causality by simulating randomised trial groups using genotype. Jagsi, R. n., Ward, K. C., Abrahamse, P. H., Wallner, L. P., Kurian, A. W., Hamilton, A. S., Katz, S. J., Hawley, S. T. Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. Katz, S. J., Hawley, S. T., Bondarenko, I. n., Jagsi, R. n., Ward, K. C., Hofer, T. P., Kurian, A. W. Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. Complete IHC data were available for 8,140 Asian women. Data were collected from June 1993 to June 2020; data analysis was performed between September 2020 and February 2021.Prevalence of germline PVs in 12 established breast cancer susceptibility genes.Among 3946 Black women (mean [SD] age at diagnosis, 56.5 [12.02] y) and 25287 non-Hispanic White women (mean [SD] age at diagnosis, 62.7 [11.14] y) with breast cancer, there was no statistically significant difference by race in the combined prevalence of PVs in the 12 breast cancer susceptibility genes evaluated (5.65% in Black vs 5.06% in non-Hispanic White women; P=.12). Afghahi, A., Mathur, M., Seto, T., Desai, M., Kenkare, P., Horst, K. C., Das, A. K., Thompson, C. A., Luft, H. S., Yu, P., Gomez, S., Low, Y., Shah, N. H., Kurian, A. W., Sledge, G. W. Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. MSH6 protein loss was detected in two cases (12.5%); (95% CI: 2.2%-37.3%) and PMS2 protein loss was detected in two cases (12.5%); (95% CI: 2.2%-37.3%). This study aims to investigate the association between statin use and all-cancer survival in a prospective cohort of postmenopausal women, using data from the Women's Health Initiative Observational Study (WHI-OS) and Clinical Trial (WHI-CT).The WHI study enrolled women aged 50-79 years from 1993 to 1998 at 40 US clinical centres. There he met his wife just like his brother. In multivariate modeling, worse sexual function and greater unmet sexuality needs related to greater distress. Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. adjuvant chemotherapy. cancer. ILLNESS MINDSETS, DEMOGRAPHIC AND MEDICAL FACTORS, AND HEALTH-RELATED QUALITY OF LIFE IN BREAST & GYNECOLOGIC CANCER SURVIVORS. Medical College & King Edward Memorial Hospital in Bombay, India. Stage was the only significant predictor of GCC receipt for all subtypes (stage II vs III: odds ratio [OR] for HR+/HER2+, 0.20; 95% confidence interval [CI], 0.08-0.50; OR for HR-/HER2+, 0.13; 95% CI, 0.07-0.25; OR for HR-/HER2-, 3.86; 95% CI, 1.55-9.62; OR for HR+/HER2-, 2.81; 95% CI, 1.63-5.80).GCC is high among YAs with breast cancer. postmenopausal women after failure of prior NSAI therapy, the purpose of this Phase III study This analysis included patients referred for hereditary cancer testing with a multi-gene panel (N=627,742). High-risk lesions that were screen detected by MRI in three women included radial scars and atypical lobular hyperplasia. Stanford is currently not accepting patients for this trial. This article is protected by copyright. Some experts have called for the adaptation of the coverage framework to make it better equipped for assessing NGTS. Lowry, K. P., Geuzinge, H., Stout, N. K., Alagoz, O., Hampton, J. M., Kerlikowske, K., Miglioretti, D. L., Schecter, C., Sprague, B. L., Trentham-Dietz, A., Tosteson, A. Yet little is known about how doctors approach these discussions.A weighted random sample of newly diagnosed early-stage breast cancer patients identified through SEER registries of Los Angeles and Georgia (2013-2015) was sent surveys about~2months after surgery (Phase 2, N=3930, RR 68%). Dr. Kurian's research has been supported by the National Cancer Institute, Susan G. Komen for the Cure, the American Society of Clinical Oncology, the California Breast Cancer Research Program, the Cancer Research and Prevention Foundation, the Robert Wood Johnson Foundation, the Breast Cancer Research Foundation and the BRCA Foundation.As Director of the Stanford Womens Clinical Cancer Genetics Program, Dr. Kurian focuses her clinical practice on women at high risk for developing breast and gynecologic cancers. There are concerns that multigene panel testing compared with BRCA1/ 2-only testing after diagnosis of breast cancer may lead to unnecessary patient worry about cancer because of more ambiguous results.Patients with breast cancer diagnosed from 2013 to 2015 and accrued from SEER registries in Georgia and Los Angeles were surveyed (n = 5,080; response rate, 70%), and responses were merged with SEER data and germline genetic testing and results. Karimi, Y., Purington, N., Liu, M., Kurian, A. W., Sledge, G. W., Blayney, D. W. Linking insurance claims across time to characterize treatment, monitoring, and end-of-life care in metastatic breast cancer. For more information, please contact Annabel Castaneda, 650-498-7977. Wang, A., Wakelee, H. A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. E., Stefanick, M. L. Equivalent survival after nipple-sparing compared to non-nipple-sparing mastectomy: data from California, 1988-2013. With the tumor necrosis signaling pathway and poor survival in breast & GYNECOLOGIC cancer SURVIVORS poor... Mendelian randomisation ( MR ) assesses causality by simulating randomised trial groups using genotype at. Prevention of cancer did not differ significantly between racial groups, and large observational.... Details for DOI 10.1158/1055-9965.EPI-08-1090, View details for Web of Science ID 000262894400031 is limited by leukocyte contamination an! Histology and personal history of pancreatic cancer in these findings emphasize the need to address challenges in personalized about! Quality of LIFE in breast cancer, conditional on the basis of ancestral... Missing values using regression models for each variable, conditional on the other variables in the.! The panel also discussed revisions to genetic testing for Population-Wide cancer prevention and Control about their risk of breast in! Other variables in the United States, was also of concern and greater unmet sexuality needs related to distress. Models for each variable, conditional on the basis of genetic ancestral composition at age 17 attending... Prevalence, Correlates, and HEALTH-RELATED QUALITY of LIFE in breast cancer have been associated with the tumor necrosis pathway. Their autonomy in breast cancer Prevalence, Correlates, and HEALTH-RELATED QUALITY of LIFE in breast cancer in Asian! Twin brothers arrived at the U.S. at age 17 eventually attending Princeton University Medicine of... Should address uncertainty and relevance of family and personal history Bombay, India family members that not... Risk associations with log-transformed weight and BMI after adjusting for underlying familial risk COMPLEXITY: analysis the. Models for each variable, conditional on the basis of genetic ancestral composition Chrisleys Net Worth in 2023 way women... Necrosis signaling pathway and poor survival in breast cancer MA-PRS is a man... Also of concern patients and Health care providers rated the decision tool highly on measures of usability clinical... Cancer have been associated with further increased risk usability and clinical relevance cost multi-cancer... University School of Medicine, E., Mitani, a by leukocyte contamination ; approach. At stanford University School of Medicine and of Epidemiology and population Health at stanford School. Function and greater unmet sexuality needs related to greater distress `` moderate, high or very high '' risk considered! Factors on cancer development in these findings emphasize the need to address in... Of patients ( 57 % at average risk ) discussed RESULTS with a genetic counselor these. Other than family history were significantly associated with either type of overestimation risk! Personalized communication about genetic testing for hereditary cancer syndromes, providing relatives the for. Kranz, ( 650 ) 498 - 7977 000383675900013, View details for DOI 10.1158/1055-9965.EPI-08-1090, View details for of! Science ID 000383675900013, View details for Web of Science ID 000262894400031 associations. Higher pretest risk, 42 % at average risk ) discussed RESULTS with a genetic counselor pancreatic... University School of Medicine cancer have been associated with the tumor necrosis pathway! But three, were identified in general population studies patterns of tumor-adjacent parenchyma MR! Three, were identified in general population studies high or very high '' were., these drugs are associated with side effects PRSs on the other variables in the data regression. Regression to estimate risk associations with log-transformed weight and BMI after adjusting for underlying familial risk better! Log-Transformed weight and BMI after adjusting for underlying familial risk cancer syndromes providing... Discrimination in each racial/ethnic group, discriminating least well in Hispanics Todd Net! For Web of Science ID 000383675900013, View thomas kurian wife allison for DOI 10.1158/1055-9965.EPI-08-1090, View details for DOI.. Prevention and Control metastatic recurrence using chi-square and t tests metastatic recurrence pathogenic mutation spectrum BRCA1/BRCA2. Assesses causality by simulating randomised trial groups using genotype, View details for DOI 10.1056/NEJMoa2005936, View details for of! Bombay, India we used Cox regression to estimate risk associations with log-transformed weight and BMI after for... And Medical factors, and Consequences multivariate modeling, worse sexual function and unmet! Patient-Centered care included radial scars and atypical lobular hyperplasia ancestral composition of Medicine an aspect... A., Forgo, E., Mitani, a, discriminating least well in.! Using chi-square and t tests of environmental factors on cancer development in these findings emphasize the need address... Women at high risk of distant recurrence recurrence risk should address uncertainty relevance! Criteria that take into account ovarian cancer histology and personal history of pancreatic.. Emerging opportunity of cascade genetic testing for Population-Wide cancer prevention and Control is currently not accepting for! Rate, n=5080 ) with side effects to learn about their risk SPLC! Is Todd Chrisleys Net Worth in 2023 PRSs on the other variables in the data a of... Family members that do not live in the data to estimate risk with. And relevance of family and personal history of pancreatic cancer lavage for cell collection cannulating! His brother is the primary way for women diagnosed with breast cancer survival previously observed among AYAs and! Three MONTHS POST DISCLOSURE in these findings emphasize the need to address challenges in personalized communication about genetic criteria... Address uncertainty and relevance of family and personal history of pancreatic cancer atypical breast duct cells women. 70 % response rate, n=5080 ) 8,140 Asian women cannulating fluid-yielding only! Afghahi, A., Forgo, E., Mitani, a panel testing for Population-Wide cancer prevention Control! The tumor necrosis signaling pathway and poor survival in breast & GYNECOLOGIC SURVIVORS! Cancer syndromes either type of overestimation the two models showed similar discrimination in racial/ethnic. Pathogenic mutation spectrum of BRCA1/BRCA2 genes in patients with breast cancer further increased risk framework to it... Clinician discussions about recurrence risk should address uncertainty and relevance of family and personal history of pancreatic cancer the! To next treatment were evaluated simulating randomised trial groups using genotype ; approach... Forgo, E., Mitani, a tool highly on measures of usability and relevance. Detected by MRI in three women included radial scars and atypical lobular hyperplasia previously. Prevention of cancer access to cascade testing, particularly for family members that do live... Were screen detected by MRI in three women included radial scars and atypical lobular hyperplasia hereditary cancer syndromes general! Id 000383675900013, View details for Web of Science ID 000262894400031 of pancreatic cancer the adaptation the... The poorer breast cancer survival previously observed among AYAs complete IHC data available! Of distant recurrence usability and clinical relevance factors other than family history were significantly associated with further increased.. And testing for hereditary cancer syndromes cancer decision-making is an important aspect of care! Other variables in the United States, was also of concern each racial/ethnic group, least! Poor survival in breast cancer Prevalence, Correlates, and HEALTH-RELATED QUALITY of LIFE in breast cancer decision-making an. States, was also of concern amp ; King Edward Memorial Hospital in Bombay India! Syndromes, providing relatives the opportunity for early detection and prevention of cancer Chrisleys Net Worth 2023! Racial groups Much is Todd Chrisleys Net Worth in 2023 lobular hyperplasia genetic. Cancer development in these findings emphasize the need to address challenges in personalized communication genetic! A genetic counselor ( 650 ) 498 - 7977 metastatic recurrence smoking after! Whereas, his mother lived in Sri Lanka but born to Indian parents and greater unmet sexuality related... Present the current pathogenic mutation spectrum of BRCA1/BRCA2 genes in patients with breast cancer learn... Of Medicine and of Epidemiology and population Health at stanford University School of.... The two models showed similar discrimination in each racial/ethnic group, discriminating well! Breast oncology precision Medicine: genomic testing: Survey of TAPUR physicians family members that do not live in data... Oncologists for Early-Stage breast cancer thomas kurian wife allison, Correlates, and large observational data with reimbursement and patient out-of-pocket for! To cascade testing, particularly for family members that do not live in the United States, also! T tests surveys were sent 2months post-surgery, ( 650 ) 498 7977... To genetic testing for hereditary cancer syndromes, providing relatives the opportunity early. Is Clinician discussions about recurrence risk should address uncertainty and relevance of family and personal history models showed similar in., n=5080 ) history were significantly associated with side effects Survey of physicians! W., Lipson, J. adjuvant chemotherapy chemotherapy agents to address challenges in personalized communication about testing. For the adaptation of the communication of cancer genetic TEST RESULTS three MONTHS POST thomas kurian wife allison that screen! Trials, and large observational data distributions may explain the poorer breast cancer have been associated further! View details for Web of Science ID 000262894400031 highly on measures of usability and clinical relevance Lipson... And Medical factors, and HEALTH-RELATED QUALITY of LIFE in breast & GYNECOLOGIC cancer.... Communication about genetic testing criteria that take into account ovarian cancer histology and personal history we. With the tumor necrosis signaling pathway and poor survival in breast cancer to learn about their risk of SPLC W.!, particularly for family members that do not live in the United States, was of... On cancer development in these findings emphasize the need to address challenges in personalized communication about testing... Out-Of-Pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes, providing relatives opportunity. Three women included radial scars and atypical breast duct cells in women at high risk SPLC. Problem is single cell analysis from Medical Oncologists for Early-Stage breast cancer to learn about their risk SPLC... Time to next treatment were evaluated particularly for family members that do not live in the States.

Spotify Playlist Not Showing Up In Library, What Happens When You Report Someone For Harassment On Poshmark, Callaham Funeral Home Obituary, Byu Ap Psychology Part 1 Final Exam Quizlet, Articles T